Brain disorders like Parkinson's disease (PD) or Alzheimer's disease (AD) start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early ...

Brain disorders like Parkinson’s or Alzheimer’s Disease start to develop in patients much earlier than when their first ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data ...

Delphi-MD employs direct electrophysiological imaging technology to provide real-time insights into brain network function.

Collaboration with KU Leuven, [led by global leader Peter Vangheluwe, PhD, a longstanding partner of The Michael J. Fox Foundation] will leverage Large Quantitative Models (LQMs) and other advanced AI ...

The room set-up is basically divided into 5 sections and focused on three major disease states—depression, Parkinson’s, and opioid addition—corresponding with our classroom content to this point in ...

A technique that combines super-resolution microscopy with advanced computational analysis could identify early signs of Parkinson’s disease ...

The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...

Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...

Advancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...

Researchers have developed an 8-channel neural stimulation chip that delivers exponential waveforms with 98% power efficiency ...